Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CVT Plans Regadenoson NDA Submission As Cardiac Stress Agent For 2006

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

CV Therapeutics expects to wrap-up two Phase III trials of its selective A2A-adenosine receptor agonist regadenoson (CVT-3146) in the third and fourth quarters, in time for a 2006 NDA submission

You may also be interested in...

CV Therapeutics submits regadenoson

CV Therapeutics submits regadenoson: CV Therapeutics and Astellas submit an NDA for their novel cardiac imaging stress agent regadenoson May 14. The application is supported by two Phase III trials, which demonstrated noninferiority compared to Astellas' currently marketed stress agent Adenoscan (adenosine). CVT is highlighting a potential safety benefit for regadenoson over competing stress agents, including the market leader Adenoscan (1Pharmaceutical Approvals Monthly May 2005, p. 12). The filing triggers a $7 million payment from Astellas to CVT; upon approval CVT would receive another $12 million. CVT is also in the process of reshaping its sales force and curtailing R&D expenses to focus on a label expansion of its second-line angina drug Ranexa (ranolazine) and to launch regadenoson in mid-2008 following approval...

Advanced Contrast Agents Aim To Improve Cost, Convenience Of Cardiac Imaging

Diagnosis of cardiovascular disease could become less costly and invasive if the alternatives to nuclear imaging and X-ray angiography that dominate the late-stage imaging agent pipeline live up to their promise.

CVT begins second regadenoson study

CV Therapeutics has initiated a second cardiac perfusion imaging trial of its pharmacologic stress agent regadenoson (CVT-3146), the firm announces April 26. CVT and partner Fujisawa plan to submit an NDA "as quickly as possible." CVT is highlighting a potential safety benefit via regadenoson's selectivity for the A2A-adenosine receptor, responsible for coronary vasodilation. The first Phase III trial started in October 2003...





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts